Yttrium chloride Y-90 is used in targeted radiotherapy for liver tumors, especially in hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer and neuroendocrine tumors (NETs), via a procedure called radioembolization (RE) or selective internal radiation therapy (SIRT). Y-90 microspheres are delivered to tumors via the hepatic artery, where the high-energy beta particles from Y-90 destroy the tumor cells with minimal damage to surrounding healthy liver tissue. It can be used as a standalone treatment, in combination with systemic chemotherapy, or to downstage tumors for other procedures like transplantation. The directory classifies it as a commercial API with a mineral/inorganic source/manufacturing origin. Other names for this substance include Ytracis and Yttriga. Its PubChem CID is 71586740.
Yttrium chloride Y-90
| CAS No | 39271-65-3 |
|---|---|
| Molecular Formula | Cl3Y |
| Molecular Weight | 196.26 g/mol |
| Synonyms | trichloro(90Y)yttrium-90 |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Yttrium chloride Y-90 is used in targeted radiotherapy for liver tumors, especially in hepatocellular carcinoma (HCC) and liver metastases from colorectal cancer and neuroendocrine tumors (NETs), via a procedure called radioembolization (RE) or selective internal radiation therapy (SIRT).
The listed CAS number is 39271-65-3.
The listed molecular formula is Cl3Y.
The listed molecular weight is 196.26 g/mol.
trichloro(90Y)yttrium-90.
The source lists Ytracis and Yttriga.